Nifuratel

Nifuratel
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	G01AX05 (WHO) ;
Identifiers
	IUPAC name 5-[(Methylthio)methyl]-3-{[(1E)-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one;
CAS Number	4936-47-4 ;
PubChem CID	6433427;
ChemSpider	4938579;
UNII	U60U6P08SP;
KEGG	D01050 ;
ECHA InfoCard	100.023.251
Chemical and physical data
Formula	C10H11N3O5S
Molar mass	285.28 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CSCC1CN(C(=O)O1)/N=C/C2=CC=C(O2)[N+](=O)[O-];
	InChI InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+; Key:SRQKTCXJCCHINN-NYYWCZLTSA-N;
	(verify)

Nifuratel (brand name Macmiror, or—in combination with nystatin—Macmiror Complex) is a drug used in gynecology. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.

Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp.^[1]

Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is Trichomonas vaginalis or Candida strains such as Candida albicans.

Side effects appear to be minimal or non-existent and it has a safe toxicological profile.^[2]

References

^ Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey
^ Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Werner Mendling, Federico Mailland Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.

[1] Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey

[2] Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Werner Mendling, Federico Mailland Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.

[1]

[2]